UN PREMIO A SOSTEGNO DELLA RICERCA NEL CAMPO DELLA BATTERIOTERAPIA ORALE

 

“Dal 2010 ogni due anni il Gruppo costituito dalla Farmagens Health Care e la S.I.F.FR.A FARMACEUTICI assegna un riconoscimento per l’impegno e i risultati ottenuti nelle ricerche in campo Farmacogenomico e Nutrigenomico.”

Augusto Sannetti, Imprenditore Farmaceutico e Promotore della Borsa di Studio

Augusto Sannetti, Imprenditore Farmaceutico e Promotore della Borsa di Studio

 

La FARMAGENS HEALTH CARE è oggi una delle più importanti realtà Internazionali dedita alla ricerca e allo sviluppo biotecnologico in diverse aree terapeutiche, come l’Apparato Cutaneo, l’Apparato Respiratorio, le Vie Urogenitali e il Tratto Gatrointestinale, che interessano in modo particolare la prevenzione e la cura della salute della donna.

Una divisione della FARMAGENS HEALTH CARE è totalmente dedicata alla ricerca, sviluppo e promozione di studi e protocolli terapeutici nelle diverse aree terapeutiche di interesse.

La FARMAGENS HEALTH CARE in collaborazione con una importante società di ricerca e produzione nel campo della NUTRIGENOMICA, la SIFFRA FARMACEUTICI, ha istituito, a partire dal 2010, una borsa di studio per la ricerca nel campo della Batterioterapia Orale finalizzata ad incentivare ricerche in campo Farmacogenomico e Nutirgenomico con specifici focus sul ruolo del PROBIOMA UMANO e le correlazioni che possono influenzare patologie infiammatorie, alterazioni metaboliche e neoplasie con particolare riferimento agli aspetti che interessano la specificità femminile.

La borsa di studio è una iniziativa che viene riproposta ogni 3 anni attraverso una comunicazione rivolta alle società scientifiche nazionali ed internazionali maggiormente impegnate nella ricerca e nella clinica delle aree terapeutiche: Gastroenterologia, Dermatologia, Infezioni delle Vie Respiratorie, Oncologia e Ginecologia.

Per saperne di più sull’argomento guardate il video di presentazione della Borsa di Studio.

RICERCHE E STUDI RELATIVI ALLE BORSE DI STUDIO PRECEDENT:

Nel 2010 dal Dott. Lucio Lombardo per i lavori:

 

1) New Insights into Lactobacillus and functional intestinal disorders.

 

Abstract

 

Intestinal microflora can be considered as a ''dynamic system'' that actively interacts with the intestinal epithelium and the local immune system. It synthesizes antimicrobial substances (bacteriocins), vitamins (PP, B1, B6, B12), it produces a major intestinal nutrient (butyric acid) and interacts in a competitive fashion with the pathogens. Lactobacilli concentration (Gram+, Gram variable, facultative anaerobes) is generally decreased in irritable bowel syndrome (IBS) patients. This syndrome has, until recently been considered to be ''functional'', whereas, in fact, it may result from previous enteritis (in up to 31% of patients), featuring a persistent low-grade intestinal inflammation and a reduction in interleukin-10 (IL-10) concentration. Some Lactobacilli strains (e.g. L. paracasei subsp. paracasei) in vitro lead to normalisation of the hypercontractility of the smooth muscle cells. A growing body of clinical findings indicates that some ''genetically stable'' strains of Lactobacilli may be useful in the treatment, even long term, of IBS, and reduce the postoperative infection rate, especially in critically ill patients (orthotopic liver transplant, severe pancreatitis). However, some Lactobacilli, ''not genetically stable'', used in the treatment of neutropenic patients during chemotherapy and in pediatric patients submitted to gastrojejunostomy, have been reported to lead to bacteremia and endocarditis. These effects may be due to transfer of bacteria and genetic material. Therefore, the confirmed genetic stability and the fact that no antibiotic resistance occurs are fundamental requisites for the use of Lactobacilli in certain disorders of the gastrointestinal tract, such as, for instance, IBS. In conclusion, ''genetically stable'' Lactobacilli (L. paracasei subsp. Paracasei F19) have recently become available, representing an exiting new field in clinical studies and for treatment purposes, offering guarantees of safety also for long-term use. Careful personalized evaluation, as always in medical practice, is necessary in order to gain further insight into, and to validate with additional studies, the role of ''genetically stable'' Lactobacilli in the treatment of IBS

 

2) PPI Use and SIBO Predisposition or Cause?

 

Nel 2013 dal Dott. Nardone Gerardo e dalla Dott. ssa Debora Compare per il lavoro:

 

1)Lactobacillus paracasei F19 versus placebo for the prevention of proton pump inihibitor-induced bowel symptoms: A randomized clinical trial.

 

Abstract

 

BACKGROUND:

 

Proton pump inhibitors may foster intestinal dysbiosis and related bowel symptoms.

 

AIM:

 

To evaluate the effect of Lactobacillus paracasei F19 on bowel symptom onset in patients on long-term proton pump inhibitors.

 

METHODS:

 

In this randomized, double-blind, placebo-controlled study, patients with typical gastroesophageal reflux disease symptoms receiving pantoprazole 40 mg/d for six months were randomly assigned to receive: (A) Lactobacillus paracasei F19 bid for three days/week for six months; (B) placebo bid for three days/week for six months; (C) Lactobacillus paracasei F19 bid for three days/week for three months and placebo bid for three days/week for the following three months; (D) placebo bid for three days/week for three months and Lactobacillus paracasei F19 bid for three days/week for the following three months. Bloating, flatulence, abdominal pain and bowel habit were assessed monthly.

 

RESULTS:

 

100/312 patients were enrolled. In the parallel groups, the treatment-by-time interaction affected bloating (p = 0.015), while Lactobacillus paracasei F19 treatment alone affected flatulence (p = 0.011). Moreover, the treatment-by-time interaction significantly affected the mean score of bloating (p = 0.01) and flatulence (p < 0.0001), the mean stool form (p = 0.03) and mean stool frequency/week (p = 0.016). Analysis of the cross-over groups, limited to the first three months because of carry-over effect, confirmed these results.

 

CONCLUSION:

Lactobacillus paracasei F19 supplementation prevents bowel symptom onset in patients on long-term proton pump inhibitors.

BORSA DI STUDIO 2016

Per informazioni inviare una e-mail indicando come riferimento “Borsa di studio 2016” al seguente indirizzo:

info@farmagens.it

 

Per saperne di più sull'argomento guardate il video di presentazione della Borsa di Studio.